BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report issued on Saturday. The brokerage set a “sell” rating on the medical technology company’s stock.

BIOLASE Price Performance

Shares of BIOLASE stock opened at $0.15 on Friday. The business’s fifty day moving average price is $0.15 and its two-hundred day moving average price is $0.77. The company has a debt-to-equity ratio of 34.06, a current ratio of 1.26 and a quick ratio of 0.68. The company has a market capitalization of $4.83 million, a P/E ratio of 0.00 and a beta of 0.71. BIOLASE has a 1-year low of $0.13 and a 1-year high of $32.09.

BIOLASE (NASDAQ:BIOL) last posted its quarterly earnings data on Thursday, March 21st. The medical technology company reported ($1.76) EPS for the quarter. BIOLASE had a negative return on equity of 555.22% and a negative net margin of 41.97%. The firm had revenue of $13.49 million during the quarter.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.